Adoptive cellular immunotherapy of cancer

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 89-97

  Winter, Hauke ^a   Fox, Bernard A ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; EFFECTOR CELL; IMMUNE RESPONSE; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD3; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; NEOPLASMS; PHYTOHEMAGGLUTININS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 0032955245     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Allen C, Hogg N: Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology (1985) 55:289.
2. Homy HP, Horst HA: Lymphoreticular infiltrates in adenocarcinoma of the large intestine. Pathol Res Pract (1987) 182:222.
3. Homy HP, Horst HA: Lymphoreticular infiltrates in invasive ductal breast cancer. A histological and immunohistological study. Virchows Arch A Pathol Anat Histopathol (1986) 409:275.
4. Brocker EB, Zwadlo G, Suter L, Brune M, Sorg C: infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer immunol Immunother (1987) 25:81.
5. Evans R: Macrophages in syngeneic animal tumours. Transplantation (1972) 14:468.
6. Fidler IJ: Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res (1974) 34:1074.
7. Chakraborty NG, Okino T, Stabach P, Padula SJ, Yamase H, Morse E, Sha'afi RI, Twardzik DR, Shultz LJ, Mukherji B: Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in SCID mice. in vivo (1991) 5:609.
8. Fidler IJ: Macrophages and metastasis - a biological approach to cancer therapy. Cancer Res (1985) 45:4714.
9. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C: Macrophages and angiogenesis. J Leukoc Biol (1994) 55:410.
10. Mantovani A, Ming WJ, Balotta C, Abdeljalil B, Bottazzi B: Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta (1986) 865:59.
11. Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science (1980) 208:1469.
12. Lopez M, Fechtenbaum J, David B, Martinache C, Chokri M, Canepa S, De Gramont A, Louvet C, Gorin I, Mortal O, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: A pilot study. J Immunother (1992) 11:209.
13. Andreesen R, Hennemann B, Krause SW: Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives [In Process Citation]. J Leukoc Biol (1998) 64:419. The rationale for the use of macrophages in cancer therapy is reviewed with emphasis on recent clinical applications in the treatment of patients.
14. Lacema LV Jr, Stevenson GW, Stevenson HC: Adoptive cancer Immunotherapy utilizing lymphokine activated killer cells and gamma interferon activated killer monocytes. Pharmacol Ther (1988) 38:453.
15. Hennemann B, Scheibenbogen C, Schumichen C, Andreesen R: intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol (1995) 18:19.
16. Eymard JC, Lopez M, Cattan A, Bouche O, Adjizian JC, Bernard J: Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer (1996) 32A:1905.
17. Hennemann B, Rehm A, Kottke A, Meidenbauer N, Andreesen R: Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes. J Immunother (1997) 20:365.
18. Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML, Lallot C, Eber M, Bartholeyns J, Poindron P, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with nonsmall-cell lung cancer: Toxicity and immunomodulatory effects. Cancer immunol immunother (1991) 33:319.
19. Deo YM, Graziano RF, Repp R, van de Winkel JG: Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today (1997) 18:127.
20. Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF: Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol (1998) 160:1677.
21. Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM: Bispecific antibody-dependent cellular cytotoxicity of HER2/neu- overexpressing tumor cells by Fc gamma receptor type 1-expressing effector cells. Cancer Res (1997) 57:4008.
22. Mazumder A, Rosenstein M, Rosenberg SA: Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes. Cancer Res (1983) 43:5729.
23. Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA: Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res (1982) 42:913.
24. Cheema AR, Hersh EM: Local tumor immunotherapy with in vitro activated autochithonous lymphocytes. Cancer (1972) 29:982.
25. Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA: Phase I study of the adoptive Immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer (1984) 53:896.
26. Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin immunol (1995) 7:704.
27. Vujanovic NL, Basse P, Herberman RB, Whiteside TL: Antitumor functions of natural killer cells and control of metastases. Methods (1996) 9:394.
28. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res (1996) 2:161.
29. Rosen FS, Cooper MD, Wedgwood RJ: The primary immunodeficiencies. N Engl J Med (1995) 333:431.
30. Ullum H, Gotzsche PC, Victor J, Dickmelss E, Skinhof P, Pedersen BK: Defective natural immunity: An early manifestation of human immunodeficiency virus infection. J Exp Med (1995) 182:789.
31. Ho M, Jaffe R, Miller G, Breinlg MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 45:719.
32. Fox BA, Rosenberg SA: Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target- recognition repertoires. Cancer Immunol Immunother (1989) 29:155.
33. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA: In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol (1980) 125:238.
34. Lefor AT, Rosenberg SA: The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis. J Surg Res (1991) 50:15.
35. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Selpp CA, Custer MC, Rosenberg SA: In vivo administration of purified human interleukln 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells In vivo with recombinant IL 2. J Immunol (1985) 135:2865.
36. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA: In vivo administration of purified human interleukln 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 134:157.
37. Rosenberg SA: Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod (1984) 3:501.
38. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 13:688. Combined results of seven phase II clinical trials of RCC patients with high dose IL-2 therapy (600 000 or 720 000 IU/kg iv bolus) showed overall 5% CR and 9% PR rates and a drug related death rate of 4%.
39. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI, et al. Randomized comparison of high-dose and low-dose intravenous interleukin- 2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol (1994) 12:1572.
40. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 210:474. The response rates and side-effects in 652 cancer patients treated with a high dose of IL-2 alone (iv bolus), or in combination with activated immune cells (LAK, TIL), cytokines (TNF, IFNα), monoclonal antibody, directed against melanoma or colorectal cancer antigens and cyclophospheamide are reviewed.
41. Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Brands RF: Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res (1990) 50:6302.
42. Stels RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW d, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Cin Oncol (1990) 8:1618.
43. Kimura H, Yamaguchi Y: Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer (1996) 14:301.
44. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, Whiteside TL: Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol (1995) 154:281.
45. Whiteside TL, Vujanovic NL, Herberman RB: Natural killer cells and tumor therapy. Curr Top Microbiol Immunol (1998) 230:221.
46. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 233:1318.
47. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst (1987) 79:1067.
48. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and lnterleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med (1988) 319:1676.
49. Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, Budd GT, Sergi JS, Bauer L, Gibson V, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res (1991) 51:4199. This study reports the in vitro cytolytic activity of TIL against autologous and allogeneic turnor, but no clinical responses were observed in 25 patients with RCC treated with continuous infusion of IL-2 with or without TIL.
50. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, deKemion J, Figlin R: Interferon-alpha primed tumor-infiltrating lymphocytes combined with in interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol (1993) 150:1384.
51. Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA: Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst (1991) 83:932. TIL from patients experiencing turnor regression showed highly increased lysis of autologous turnor cells compared to TIL derived from patients that failed to respond. The cytotoxicity declined markedly after in vitro culture for longer than 45 days.
52. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with In vivo tumor rejection. Proc Natl Acad Sci USA (1994) 91:6458.
53. Shu SY, Chou T, Rosenberg SA: Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol (1987) 139:295.
54. Shu S, Chou T, Rosenberg SA: In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol (1986) 136:3891.
55. Chou T, Chang AE, Shu SY: Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitizaton. Culture requirements and characterization of immunologic specificity. J Immunol (1988) 140:2453. The therapeutic efficacy of IVS cells is dependent upon the concentration of IL-2 present during in vitro activation. IVS cells activated in 10 IU/ml IL-2 display higher antitumor activity than LAK cells.
56. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res (1993) 53:1043. First report that described in vitro sensitization of TVDLN cells using autologous turnor. Adoptive transfer of these activated T-cells conferred DTH to autologous tumor.
57. Inoue M, Plautz GE, Shu S: Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res (1996) 56:4702.
58. Peng L, Shu S, Krauss JC: Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol (1997) 178:24.
59. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol (1991) 147:729. Lymph nodes draining weakly immunogenic MCA tumors contain nontherapeutic turnor-sensitized pre-effector cells. Subsequent polyclonal in vitro activation with anti-CD3 enables TVDLN cells to become therapeutic. Activated TVDLN cells did not exhibit cytotoxicity against autologous tumor.
60. Yoshizawa H, Sakal K, Chang AE, Shu SY: Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive Immunotherapy. Cell Immunol (1991) 134:473.
61. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol (1997) 15:796. This was the first clinical trial using in vitro anti-CD3 activated TVDLN expanded in low doses of IL-2. The TVDLN cells showed tumor-specific release of GM-CSF and IFN-γ. Two CR and three PR were observed in patients with renal cell cancer.
62. Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS: Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J lmmunol (1994) 152:1277.
63. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser OB, Shu S: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg (1998) 89:42. This was the first clinical trial adoptively transferring TVDLN cells activated in vitro with SEA and anti-CD3.
64. Wahl WL, Strome SE, Nabel GJ, Plaute GE, Cameron MJ, San H, Fox BA, Shu S, Chang AE: Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene. J Immunother Emphasis Tumor Immunol (1995) 17:1.
65. Wahl WL, Sussman JJ, Shu S, Chang AE: Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J Immunother Emphasis Tumor Immunol (1994) 15:242.
66. Rosenberg SA: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst (1996) 88:1635. Description of the process of identification of genes encoding melanoma antigens (MART I, gp 100, tyrosinase, TRP1, p15 and β-catenin) utilizing TIL derived from melanoma patients responding to adoptive immunotherapy.
67. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today (1997) 18:175.
68. Pardoll DM: Cancer vaccines. Nat Med (1998) 4:525. Different mechanisms of tumor-induced tolerance are reviewed and current vaccine strategies trying to induce antitumor immune responses are discussed.
69. Pardoll DM: Cancer vaccines. Trends Pharmacol Sci (1993) 14:202.
70. Livingston PO, Albino AP, Chung TJ, Real FX, Houghton AN, Oettgen HF, Old LJ: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer (1985) 55:713.
71. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol (1990) 8:1858.
72. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P: Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res (1988) 48:2975.
73. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ: Immunotherapy of malignancy by in vivo gene transfer into tumors [see comments]. Proc Natl Acad Sci USA (1993) 90:4645.
74. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol (1995) 13:399. This exellent review discusses the rationale and possible antitumor mechanisms of different cytokines released locally by genetically engineered tumor cells or biodegradable reservoirs.
75. Hellstrom KE, Hetlstrom I, Chen L: Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev (1995) 145:123.
76. Freeman AG: Hypothyroidism [letter; comment]. Lancet (1997) 349:1023.
77. Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G: Protective and curative potential of vaccination with interleukin-2- gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res (1993) 53:5067.
78. Huang AY, Bruce AT, Pardoll DM, Levitsky HI: In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 4:349.
79. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90:3539.
80. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 269:1585.
81. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278:117.
82. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med (1998) 4:321. Vaccination with a synthetic anchor-modified gp100 peptide results in highly elevated precursor frequencies of PBMC's against the native peptide. A high response rate (42%) was noted in patients with metastatic melanoma undergoing vaccination in combination with the administration of IL-2.
83. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 -binding residues. J Immunol (1996) 157:2539.
84. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer (1995) 63:883.
85. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev (1995) 145:229. This article reviews genes that code for MHC class-I restricted tumor antigens recognized by CTL and their possible clinical application.
86. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nat Med (1998) 4:328. Vaccination of melanoma patients with dendritic cells pulsed with tumor cell lysate, MAGE1, MAGE3, MELANA/MART1 or gp 100 in combination with KLH, induced antigen-specific immunity and tumor regression in 31% of patients. No sign of autoimmunity was observed.
87. Hi-T-cells derived from lymph nodes draining the weakly immunogenic MCA-205 are therapeutic following adoptive transfer.
88. Kagamu H, Shu S: Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol (1998) 160:3444.
89. Andersson EC, Christensen JP, Marker O, Thomsen AR: Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. J Immunol (1994) 152:1237.
90. Hou S, Doherty PC: Partitioning of responder CD8+ T cells In lymph node and lung of mice with Sendal virus pneumonia by LECAM-1 and CD45RB phenotype. J Immunol (1993) 150:5494.
91. Mobley JL, Dailey MO: Regulation of adhesion molecule expression by CDS T cells In vivo. I. Differential regulation of gp90MEL-14 (LECAM-1), Pgp-1, LFA-1, and VLA- 4 alpha during the differentiation of cytotoxic T lymphocytes induced by allografts. J Immunol (1992) 148:2348.
92. Mobley JL, Rigby SM, Dailey MO: Regulation of adhesion molecule expression by CDS T cells in vivo. II. Expression of L-select(n (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. J Immunol (1994) 153:5443.
93. Bashey J, Mu H-M, Lowe B, Urba W, Fox BA: Reduced L-selectin expression defines T cells in renca tumor vaccine-draining lypmph nodes with therapeutic activity. J Urology (1998) Suppl 159:196.
94. Hu HM, Urba WJ, Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor- specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol (1998) 161:3033. B16BL/6 (D5), a poorly immunogenic melanoma, primes nontherapeutic tumor-specific type 2 T-cells in TVDLN. Allo MHC-class I modified D5 sensitized therapeutic tumor-specific type 1 T-cells in the TVDLN. This paper suggests that immune deviation may play a role in tumor evasion of the immune system.
95. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more [see comments]. Immunol Today (1996) 17:138.
96. Brocker T, Karjalainen K: Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol (1998) 68:257.
97. Hege KM, Broad DF, Roberts RE, Warren GA, Fisher GA, McArthur J: T cell gene therapy of colorectal cancer with autologous CC49-zeta gene-modified CD4 and CD8 T cells. Proc Am Soc Clin Oncol (1998) 17:428a #1649.
98. Gong M, Latouche J, Krause A, Heston D, Bander N, Sadelain M: Cancer patient T cells genetically targeted to PSMA specifically lyse prostate cancer cells. (1998) submitted.
99. Winter H, Hu H-M, Urba WJ, Fox BA: Perforin deficient T cells from tumor vaccine-draining Lymph nodes mediate tumor regression. FASEB J (1998) 12:A278.
100. Peng L, Shu S, Krauss JC: Divergent roles of IFN-gamma and perforin In the elimination of tumor by adoptively transferred T cells. Proc Am Assoc Cancer Res (1998) 39 (550):3741.
101. Lucey DR, Clerici M, Shearer GM: Type 1 and type 2 cytokine dysregulation In human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 9:532.
102. Clerici M. Shearer GM, Clerici E: Cytokina dysregulation in invasive cervical carcinoma and other human neoplasias: Time to consider the TH1/TH2 paradigm [editorial; comment]. J Natl Cancer Inst (1998) 90:261. Short review, that discusses the relevance of the type 1/ type 2 paradigm in tumor immunology.
103. York IA, Rock KL: Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol (1996) 14:369.
104. Kawakami Y, Ellyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 154:3961.
105. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol (1997) 108:914.
106. Callan MF, Tan L, Annels N, Ogg GS, Wilson JO, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB: Direct visualization of antigen-specific CD8+ T cells during the primary Immune response to Epstein-Barr virus in vivo. J Exp Med (1998) 187:1395.
107. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes [In Process Citation]. J Exp Med (1998) 188:1641. Tetramers specific for either tyrosinase or melan-A revealed a frequency of 1 in 50 to 1 in 500 melanoma specific CTL derived from tumor infiltrated lymph nodes.The majority of these cells had a CD45RO' phenotype. Melan A specific CTL were highly cytolytic against autologous tumor cells and peptide-pulsed cells.
108. Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225:1487.
109. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 85(13):1091.
110. Ridolfi R, Flamini E, Riccobon A, De Paola F, Maltoni R, Gardini A, Ridolfi L, Medri L, Poletti G, Amadori D: Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol Immunother (1998) 46:185.